See All Slides -

Slides

Presentation TCT 2012

Step 6: Clinical Regulatory Pathways

Presenter: Semih Oktay

October 22, 2012

Presentation TCT 2012

Concomitant CAD and Aortic Stenosis: Implications and Revascularization Strategies

Presenter: David Hildick-Smith

October 22, 2012

$Mobilized CD 34+ Cells for Refractory Angina$

Presentation TCT 2012

Mobilized CD 34+ Cells for Refractory Angina

Presenter: Thomas Povsic

October 22, 2012

Presentation TCT 2012

Should the Presence of Diabetes Affect Decisions on PCI vs. CABG, and Which DES to Choose?

Presenter: Duk-Woo Park

October 22, 2012

Presentation TCT 2012

Role of FFR in Globally Balanced Myocardial Ischemia : Falsely Negative 99mTc Scintigram Associated with highly significant FFR

Presenter: Anupam Bhambhani

October 22, 2012

Presentation TCT 2012

“Nuggets” on Patient Selection After > 1,000 TAVR Cases (Performed and/or Proctored): Self-Expanding TAVR

Presenter: Ganesh Manoharan

October 22, 2012

Presentation TCT 2012

Early Insights on Cost-effectiveness After TAVR

Presenter: Matthew Reynolds

October 22, 2012

Presentation TCT 2012

Pharmacotherapy for Acute Coronary Syndromes/NSTEMI

Presenter: Emmanouil Brilakis

October 22, 2012

Presentation TCT 2012

Improved Patient Screening, Meticulous Access and Closure Techniques, and Lower Profile Catheter Systems Can Reduce Major Vascular Complications to <5%: The Vancouver Experience

Presenter: John Webb

October 22, 2012

Presentation TCT 2012

Mitral Valve Disease Hemodynamics, Balloon Valvuloplasty and the Edge-to-Edge Approach (Including Related Guidelines)

Presenter: Zoltan Turi

October 22, 2012

Advertisement

Slides

Step 6: Clinical Regulatory Pathways

Concomitant CAD and Aortic Stenosis: Implications and Revascularization Strategies

Mobilized CD 34+ Cells for Refractory Angina

Should the Presence of Diabetes Affect Decisions on PCI vs. CABG, and Which DES to Choose?

Role of FFR in Globally Balanced Myocardial Ischemia : Falsely Negative 99mTc Scintigram Associated with highly significant FFR

“Nuggets” on Patient Selection After > 1,000 TAVR Cases (Performed and/or Proctored): Self-Expanding TAVR

Early Insights on Cost-effectiveness After TAVR

Pharmacotherapy for Acute Coronary Syndromes/NSTEMI

Improved Patient Screening, Meticulous Access and Closure Techniques, and Lower Profile Catheter Systems Can Reduce Major Vascular Complications to <5%: The Vancouver Experience

Mitral Valve Disease Hemodynamics, Balloon Valvuloplasty and the Edge-to-Edge Approach (Including Related Guidelines)

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content